SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OCATA THERAPEUTICS
OCAT 8.4700.0%Feb 11 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant8/7/2014 11:03:15 PM
1 Recommendation

Recommended By
FJB

  Read Replies (1) of 134
 
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update

Aug 06, 2014 16:30:00 (ET)

Webcast Scheduled for Monday, August 11, 2014 at 5:00 p.m. Eastern Time

MARLBOROUGH, Mass.--(BUSINESS WIRE)--August 06, 2014-- 
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.m. EDT during which it will provide a corporate update.

Interested parties may access the call live by dialing (888) 264-3177 and using conference ID 87179264. This event is also being streamed via webcast. The webcast is available at engage.vevent.com. A replay of the call will also be available via the same link.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company's most advanced products are in clinical trials for the treatment of dry age-related macular degeneration and Stargardt's macular degeneration. ACT's preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company's intellectual property portfolio includes pluripotent stem cell platforms -- hESC and induced pluripotent stem cell (iPSC) -- and other cell therapy research programs. For more information, advancedcell.com or connect with the Company on Facebook, Twitter, LinkedIn, Google+, and YouTube.

Forward-Looking Statements
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext